Sugi Predict

Sugi Predict / Compounds / SCHEMBL10158674

SCHEMBL10158674

SCHEMBL10158674

C=C(C)COc1ccccc1I

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR174 Q9BXC1 1/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ POLB P06746 2/20 0.38
▸ GLA P06280 1/20 0.38
▸ ALDH1A1 P00352 4/20 0.37
▸ NPSR1 Q6W5P4 4/20 0.37
▸ KDM4E B2RXH2 3/20 0.37
▸ HSD17B10 Q99714 3/20 0.37
▸ LMNA P02545 3/20 0.37
▸ TSHR P16473 3/20 0.37
▸ CTSS P25774 1/20 0.36
▸ MAPT P10636 4/20 0.35
▸ HPGD P15428 1/20 0.35
▸ MEN1 O00255 4/20 0.35
▸ KMT2A Q03164 4/20 0.35
▸ TP53 P04637 3/20 0.35
▸ MAPK1 P28482 3/20 0.35
▸ USP2 O75604 2/20 0.35
▸ ALOX12 P18054 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9750660 0.86 SMN1; SMN2 (0.48) GPR174SMN1; SMN2L3MBTL1POLBGLA
SCHEMBL29457182 0.86 SMN1; SMN2 (0.48) GPR174SMN1; SMN2L3MBTL1POLBGLA
SCHEMBL9901000 0.81 SMN1; SMN2 (0.42) GPR174SMN1; SMN2L3MBTL1POLBGLA
SCHEMBL31254027 0.81 KMT2A (0.50) SMN1; SMN2L3MBTL1POLBGLAALDH1A1
SCHEMBL10870502 0.80 MEN1 (0.45) GPR174SMN1; SMN2L3MBTL1POLBGLA
SCHEMBL28541854 0.79 PKM (0.41) SMN1; SMN2POLBALDH1A1NPSR1KDM4E
SCHEMBL8390273 0.78 GAA (0.55) GPR174SMN1; SMN2L3MBTL1ALDH1A1NPSR1
SCHEMBL5784873 0.78 L3MBTL1 (0.61) GPR174SMN1; SMN2L3MBTL1POLBGLA
SCHEMBL5785927 0.78 SMN1; SMN2 (0.61) SMN1; SMN2L3MBTL1POLBNPSR1KDM4E
SCHEMBL5786743 0.78 NOTUM (0.51) SMN1; SMN2POLBGLAALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107567443-B Biaryl derivatives as GPR120 agonists 株式会社LG化学 2023-04-28 — — CN disclosed
CN-115925679-A Biaryl derivatives as GPR120 agonists 株式会社LG化学 2023-04-07 — — CN disclosed
EP-3239143-B1 BIARYL DERIVATIVE AS GPR120 AGONIST LG CHEMICAL LTD (KR) 2023-03-22 — — EP disclosed
US-20220135574-A1 BIARYL DERIVATIVE AS GPR120 AGONIST LG CHEM, LTD. (KR) 2022-05-05 — — US disclosed
US-11261186-B2 Biaryl derivative as GPR120 agonist LG CHEM. LTD. (KR) 2022-03-01 — — US disclosed
CN-108047176-B Synthesis method of dihydrobenzofuran compound with chiral quaternary carbon center 常州合全药业有限公司 2021-04-20 — — CN disclosed
US-20170349594-A1 BIARYL DERIVATIVE AS GPR120 AGONIST LG CHEM, LTD. (KR) 2017-12-07 — — US disclosed
EP-3239143-A2 BIARYL DERIVATIVE AS GPR120 AGONIST LG Chem, Ltd. (KR) 2017-11-01 — — EP disclosed
EP-2757096-A9 Inhibitors of human immunodeficiency virus replication GILEAD SCIENCES, INC. (US) 2014-11-26 — — EP disclosed
US-20140296228-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION GILEAD SCIENCES, INC. (US) 2014-10-02 — — US disclosed
US-20110028464-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) 2011-02-03 — — US disclosed
US-20110028464-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) 2011-02-03 — — US disclosed
US-20100311735-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) 2010-12-09 — — US disclosed
US-20100311735-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) 2010-12-09 — — US disclosed
US-20100305115-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) 2010-12-02 — — US disclosed
US-20100305115-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) 2010-12-02 — — US disclosed
WO-2009062285-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-22 — — WO disclosed
WO-2009062289-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-22 — — WO disclosed
WO-2009062288-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-22 — — WO disclosed
WO-2009062308-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028464-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION RTF2, REV1, RTF1 GPR174 2334/4885SMN1; SMN2 3906/4885L3MBTL1 607/4885
US-20140296228-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION RTF2, REV1, POLR1E GPR174 1880/4885SMN1; SMN2 3916/4885L3MBTL1 776/4885
US-20220135574-A1 BIARYL DERIVATIVE AS GPR120 AGONIST GPR119, GLP1R, GIPR GPR174 20/4885SMN1; SMN2 3448/4885L3MBTL1 2990/4885
US-20170349594-A1 BIARYL DERIVATIVE AS GPR120 AGONIST GPR119, GLP1R, GIPR GPR174 20/4885SMN1; SMN2 3448/4885L3MBTL1 2990/4885
US-11261186-B2 Biaryl derivative as GPR120 agonist GPR119, GPR88, FFAR1 GPR174 15/4885SMN1; SMN2 4496/4885L3MBTL1 4242/4885
US-20100305115-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION CCNY, RTF2, POLR2E GPR174 2824/4885SMN1; SMN2 4261/4885L3MBTL1 1086/4885
US-20100311735-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION RTF2, REV1, POLR1E GPR174 1880/4885SMN1; SMN2 3916/4885L3MBTL1 776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.